Amerise Biosciences Ltd (AMERISE)

Loading page…

Amerise Biosciences Ltd (AMERISE) · mywealthgrid

About

Amerise Biosciences Ltd operates in Plastic Products - Industrial within the Industrials sector.

Face value: ₹1

Market cap

₹5 Cr

P/E

736.5×

P/B

1.0×

Dividend yield

ROE

0.4%

ROCE

0.6%

Debt / equity

OPM

11.5%

EPS (TTM)

₹0.0

Book value

₹0.8

52-week high

—

52-week low

—

1,308 historical price candles were omitted because the exchange source has not been verified.

₹0.8-8.2%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of -0.7% (3-yr avg)
−Expensive at 736.5× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

52/100

Business quality: 30
Growth: 100
Valuation: 25

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Supreme Industries LimitedSUPREMEINDSUPREMEIND	₹42,926 Cr	₹42,926 Cr	₹11,326 Cr	₹1,632 Cr	13.9%	₹1,032 Cr	8.5%	19.1%	16.1%	44
Garware Hi-Tech Films LimitedGRWRHITECHGRWRHITECH	₹16,067 Cr	₹16,067 Cr	₹2,258 Cr	₹497 Cr	20.5%	₹388 Cr	16%	17.6%	13.5%	89
Finolex Industries LimitedFINPIPEFINPIPE	₹9,338 Cr	₹9,775 Cr	₹3,954 Cr	₹692 Cr	16.5%	₹615 Cr	14.6%	12.2%	9.7%	133
Kingfa Science & Technology (India) LimitedKINGFAKINGFA	₹8,958 Cr	₹8,958 Cr	₹2,222 Cr	₹314 Cr	13.1%	₹226 Cr	9.3%	23.6%	17.4%	100
Time Technoplast LimitedTIMETECHNOTIMETECHNO	₹8,869 Cr	₹9,508 Cr	₹6,445 Cr	₹922 Cr	14.6%	₹490 Cr	7.8%	18.2%	13.4%	161
Prince Pipes And Fittings LimitedPRINCEPIPEPRINCEPIPE	₹2,731 Cr	₹2,871 Cr	₹2,627 Cr	₹270 Cr	8.9%	₹102 Cr	2.8%	6.4%	4.5%	71
Apollo Pipes LimitedAPOLLOPIPEAPOLLOPIPE	₹2,255 Cr	₹2,379 Cr	₹1,125 Cr	₹49 Cr	6%	₹-15 Cr	0.4%	2.1%	0.6%	58
Jain Irrigation Systems LimitedJISLJALEQSJISLJALEQS	₹1,951 Cr	₹6,013 Cr	₹6,362 Cr	₹765 Cr	12.5%	₹-53 Cr	-0.6%	7.3%	-0.4%	230
Jai Corp LimitedJAICORPLTDJAICORPLTD	₹1,571 Cr	₹1,571 Cr	₹541 Cr	₹70 Cr	10.6%	₹93 Cr	32.9%	13.1%	11.7%	269
Premier Polyfilm LimitedPREMIERPOLPREMIERPOL	₹949 Cr	₹949 Cr	₹365 Cr	₹50 Cr	13.6%	₹35 Cr	9.4%	31.2%	24.1%	102
R M Drip And Sprinklers Systems LimitedRMDRIPRMDRIP	₹587 Cr	₹640 Cr	₹207 Cr	₹53 Cr	26.6%	₹35 Cr	17.7%	33.6%	31.5%	268
Prakash Pipes LimitedPPLPPL	₹582 Cr	₹621 Cr	₹780 Cr	₹118 Cr	15.1%	₹83 Cr	10.7%	28.6%	20.5%	—

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	—	—	—	—	—	0	10	0	0	0	0
COGS	—	—	—	—	—	0	9	0	0	0	0
Gross profit	—	—	—	—	—	—	1	—	—	—	—
	—	—	—	—	—	0	0	0	0	0	0
	—	—	—	—	—	-0	1	-0	-0	0	0
OPM %	—	—	—	—	—	—	5.7%	—	—	5.3%	11.5%
Depreciation	—	—	—	—	—	0	0	0	0	0	0
Interest	—	—	—	—	—	0	0	0	0	0	0
	—	—	—	—	—	-0	0	0	0	0	0
Profit before tax	-0	-1	-0	0	-0	-0	1	-0	-0	0	0
Tax	—	—	—	—	—	0	0	0	0	0	0
	-0	-1	-0	-0	-0	-0	1	-0	-0	0	0
PAT margin %	—	—	—	—	—	—	5.7%	—	—	5.3%	7.7%
EPS (₹)	—	—	—	—	—	-0.1	0.1	-0	-0	0	0
EPS adjusted (₹)	—	—	—	—	—	-0.1	0.1	-0	-0	0	0
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	7	7	7	7	7	7
Reserves	-2	-1	-1	-1	-1	-1
	0	0	0	0	0	0
	1	6	0	0	3	2
Total equity & liabilities	6	12	6	5	8	7
	0	0	0	0	0	0
CWIP	0	0	0	0	0	0
Investments	3	5	5	2	2	4
	3	7	1	3	6	4
Total assets	6	12	6	5	8	7

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	7%	—	—	—	—
EBITDA margin %	—	—	—	5.7%	—	—	5.3%	11.5%
EBIT margin %	—	—	—	5.7%	—	—	5.3%	11.5%
PAT margin %	—	—	—	5.7%	—	—	5.3%	7.7%
Working capital
Receivable days	—	—	—	237	—	—	0	0
Inventory days	—	—	—	0	—	—	0	0
Payable days	—	—	—	256	—	—	0	0
NWC days	—	—	—	-19	—	—	0	0
Leverage
Current ratio	—	—	0.04	0.99	0.25	1	0.01	0.3
Debt to EBITDA	—	—	—	0.15	—	—	0	0
Debt to equity	—	—	0	0.01	0.02	0	0	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0	0.8	0	0	0.02	0.04
Return ratios
Return on assets %	—	—	-6%	4.6%	-2.1%	-2.8%	0.1%	0.3%
Return on capital employed %	—	—	-6.7%	10.2%	-2.1%	-2.6%	0.2%	0.6%
Return on equity %	—	—	-6.7%	9.8%	-2.2%	-2.8%	0.2%	0.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoter	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
No. of shareholders	—	—	—	—	—	—	—	—	35,676	35,180	34,519	33,848

Promoter holding up 0 percentage points since Sep 2023.

32 deals · 18 Jan 2022 – 15 Jul 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
15 Jul 2026	SNEHA SANJEEV LUNKAD	Bulk	BSE	Sell	4,17,285	₹0.95	₹0.04 Cr
23 Apr 2026	SNEHJEEV VENTURES PRIVATE LIMITED	Bulk	BSE	Buy	3,70,000	₹0.77	₹0.03 Cr
23 Apr 2026	TINIBEN SURESHBHAI DARJI	Bulk	BSE	Sell	3,50,222	₹0.77	₹0.03 Cr
4 Feb 2026	KANCHAN PATHAK	Bulk	BSE	Buy	5,00,000	₹0.78	₹0.04 Cr
4 Feb 2026	SNEHA SANJEEV LUNKAD	Bulk	BSE	Sell	3,51,561	₹0.78	₹0.03 Cr
17 Oct 2025	RUBEENAMAHBOOBGAURI	Bulk	BSE	Sell	4,89,816	₹0.57	₹0.03 Cr
8 Jan 2025	DIPAKKUMARGAUTAM	Bulk	BSE	Sell	3,80,933	₹1.19	₹0.05 Cr
12 Nov 2024	SARDAR SINGH RANWA	Bulk	BSE	Buy	3,67,619	₹1.05	₹0.04 Cr
3 Jul 2023	SULEKHA RANI	Bulk	BSE	Sell	4,13,202	₹0.75	₹0.03 Cr
3 Jul 2023	SULEKHA RANI	Bulk	BSE	Buy	108	₹0.74	₹0.00 Cr

1–10 of 32

1 / 4

Manisha Maneklal PatelDirector
Mr. Kelash BunkarNon - Executive Independent Director
Mr. Albert HinesWhole Time Director & Chief Financial Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Amerise Biosciences Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results3 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

47 announcementsExport CSV

17 Sept 2026, 4:08 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

1 Sept 2026, 4:47 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

1 Sept 2026, 4:42 pmCorp. Action

Intimation Of Book Closure Pursuant To Regulation 42 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Book Closure PDF

1 Sept 2026, 4:40 pmAGM/EGM

Submission Of Notice Of Annual General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

AGM PDF

18 Aug 2026, 10:51 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

3 Aug 2026, 5:27 pmResult

Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Financial Results PDF

3 Aug 2026, 5:26 pmResult

Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Financial Results PDF

3 Aug 2026, 5:22 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting Held On 3Rd August 2026

Outcome of Board Meeting PDF

Date	Category	Subject	Filing
17 Sept 2026, 4:08 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
1 Sept 2026, 4:47 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	7%	—	—	—	—
EBITDA margin %	—	—	—	5.7%	—	—	5.3%	11.5%
EBIT margin %	—	—	—	5.7%	—	—	5.3%	11.5%
PAT margin %	—	—	—	5.7%	—	—	5.3%	7.7%
Working capital
Receivable days	—	—	—	237	—	—	0	0
Inventory days	—	—	—	0	—	—	0	0
Payable days	—	—	—	256	—	—	0	0
NWC days	—	—	—	-19	—	—	0	0
Leverage
Current ratio	—	—	0.04	0.99	0.25	1	0.01	0.3
Debt to EBITDA	—	—	—	0.15	—	—	0	0
Debt to equity	—	—	0	0.01	0.02	0	0	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0	0.8	0	0	0.02	0.04
Return ratios
Return on assets %	—	—	-6%	4.6%	-2.1%	-2.8%	0.1%	0.3%
Return on capital employed %	—	—	-6.7%	10.2%	-2.1%	-2.6%	0.2%	0.6%
Return on equity %	—	—	-6.7%	9.8%	-2.2%	-2.8%	0.2%	0.4%

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-0	0	-0	-0	3	-1
	0	-0	0	0	-3	2
	0	0	0	-0	0	0
Net cash flow	0	-0	0	0	0	1
Free cash flow	-0	0	-0	-0	3	-1
CFO / Operating profit %	—	10.9%	—	—	—	—

Amerise Biosciences Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

Announcements

Not in the F&O segment

No fund holdings on record

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Amerise Biosciences Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1